September 18, 2019

Alexion Announces Expansion of Global Product Development Lab in New Haven

- Total investment of approximately $10 million over the coming year -

- Opportunity for local and regional contractors, and qualified scientists and engineers -

Alexion today announced that it is expanding its Global Product Development lab, located at the company's Center of Excellence at 100 College Street in New Haven, to support the continued growth and diversification of the company's pipeline. This expansion is intended to increase the company's capacity and capabilities to advance the development of more early medicine candidates from pre-clinical studies into in clinical studies. It will also support ongoing efforts to develop new medicine delivery systems to improve patients' treatment experiences.

In addition, this planned expansion reinforces the company's commitment to Connecticut and to the city of New Haven, where Alexion was founded 27 years ago and has developed and maintained a strong presence with more than 500 employees today. Alexion anticipates investing approximately $10 million in this expansion and is looking forward to working with local and regional contractors to complete the project before the end of 2020. The expansion also represents a great opportunity to the city's and state's highly skilled and trained process development scientists, analysts and engineers to join Alexion's inspiring efforts to develop new, life-changing medicines for people living with devastating rare diseases.

Forward-Looking Statement

This press statement contains forward-looking statements, including statements related to: the Company's intent to expand its Global Product Development lab in New Haven; this expansion is designed to support the continued growth and diversification of the company's pipeline and capabilities to advance the development of more early medicine candidates from pre-clinical studies into in clinical studies; the Company's future efforts to develop new medicine delivery systems to improve patients' treatment experiences; the Company's commitment to Connecticut and to the City of New Haven; Alexion anticipates investing approximately $10 million in this expansion and is looking forward to working with local and regional contractors to complete the project before the end of 2020. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ materially from those forward-looking statements, including for example: the inability to commence, complete or any unexpected delays in connection with the planned expansion work due to expense, unanticipated interruptions or other issues that may be encountered; the anticipated expansion may not result in growth and diversification of the company's pipeline and capabilities and other expected benefits for the Company, the Company's products and for patients; and the Company may be unable to make the anticipated investments in the time anticipated, or at all; our dependence on sales from our principal product (SOLIRIS); our ability to facilitate the timely conversion of PNH patients (and any future approved indications) from SOLIRIS to ULTOMIRIS; delays (expected or unexpected) in the time it takes regulatory agencies to review and make determinations on applications for the marketing approval of our products; Alexion's inability to timely submit (or failure to submit) future applications for regulatory approval for our products and product candidates; payer, physician and patient acceptance of ULTOMIRIS as an alternative to SOLIRIS; appropriate pricing for ULTOMIRIS; future competition from biosimilars and novel products; inability to timely initiate (or failure to initiate) and complete future clinical trials due to safety issues, IRB decisions, CMC-related issues, expense or unfavorable results from earlier trials (among other reasons); decisions of regulatory authorities regarding the adequacy of our research, marketing approval or material limitations on the marketing of our products; delays or failure of product candidates to obtain regulatory approval; delays or the inability to launch product candidates due to regulatory restrictions, expense or other matters; interruptions or failures in the manufacture and supply of our products and our product candidates; failure to satisfactorily address matters raised by the FDA and other regulatory agencies regarding our products and product candidates; results in early stage clinical trials may not be indicative of full results or results from later stage or larger clinical trials

(or in broader patient populations) and do not ensure regulatory approval; the possibility that results of clinical trials are not predictive of safety and efficacy and potency of our products (or we fail to adequately operate or manage our clinical trials) which could cause us to halt trials, delay or prevent us from making regulatory approval filings or result in denial of regulatory approval of our product candidates; unexpected delays in clinical trials; unexpected concerns that may arise regarding our products and product candidates from additional data or analysis obtained during clinical trials; future product improvements may not be realized due to expense or feasibility or other factors; uncertainty of long-term success in developing, licensing or acquiring other product candidates or additional indications for existing products; inability to complete planned acquisitions due to failure of regulatory approval or material changes in target or otherwise; inability to complete acquisitions and investments due to increased competition to acquire technology; the possibility that current rates of adoption of our products are not sustained (or anticipated adoption rates are not realized); the adequacy of our pharmacovigilance and drug safety reporting processes; failure to protect and enforce our data, intellectual property and proprietary rights and the risks and uncertainties relating to intellectual property claims, lawsuits and challenges against us (including intellectual property lawsuits relating to ULTOMIRIS brought by third parties against Alexion and inter partes reviews initiated by third parties); the risk that third party payors (including governmental agencies) will not reimburse or continue to reimburse for the use of our products at acceptable rates or at all; failure to realize the benefits and potential of investments, collaborations, licenses and acquisitions; the possibility that expected tax benefits will not be realized; assessment of impact of recent accounting pronouncements; potential declines in sovereign credit ratings or sovereign defaults in countries where we sell our products; delay of collection or reduction in reimbursement due to adverse economic conditions or changes in government and private insurer regulations and approaches to reimbursement; uncertainties surrounding legal proceedings, company investigations and government investigations, including investigations of Alexion by the U.S. Securities and Exchange Commission (SEC) and U.S. Department of Justice; risks related to changes in the Company's management and management team; the risk that estimates regarding the number of patients with PNH, aHUS, gMG, NMOSD, HPP and LAL-D and other future indications we are pursuing are inaccurate; the risks of changing foreign exchange rates; risks relating to the potential effects of the Company's restructuring; risks related to the acquisition of companies and co-development and collaboration efforts; and a variety of other risks set forth from time to time in Alexion's filings with the SEC, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the period ended June 30, 2019 and in our other filings with the SEC. Alexion disclaims any obligation to update any of these forward-looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law.

Alexion Contact:
Megan Goulart, 857-338-8634
Senior Director, Corporate Communications